In a recent late-stage clinical trial, Sarepta Therapeutics’ gene therapy designed to treat Duchenne muscular dystrophy (DMD), a progressive muscle-wasting genetic disorder, failed to achieve its primary goal when administered to patients aged 4 to 7 years. Specifically, the therapy did not demonstrate statistical significance in the total assessment score of motor function when compared to patients who received a placebo over a 52-week period. DMD primarily affects young boys and typically results in a limited life expectancy beyond one’s thirties.
The gene therapy, known as Elevidys, had previously received accelerated approval from the U.S. health regulator for children aged 4 to 5 years who can walk, as opposed to the initial application seeking approval for all walking DMD patients. The company highlighted that Elevidys did meet all secondary study objectives with statistically significant outcomes and did not show any new safety concerns.
Sarepta plans to request an update from the U.S. Food and Drug Administration (FDA) to expand the therapy’s usage to other age groups based on the trial findings. Elevidys is a one-time treatment, representing a potential shift in the treatment paradigm for DMD patients, as current therapies necessitate ongoing use. Of the four “exon-skipping” therapies intended for a specific subset of DMD patients with specific genetic mutations, three are developed by Sarepta. These therapies require weekly infusions and function by skipping specific gene segments, known as exons, in order to promote the formation of shorter dystrophin protein forms.
Roche holds commercial rights to Elevidys outside the United States, while Sarepta retains responsibility for clinical development and shares the associated costs with Roche.
The disappointing results from Sarepta Therapeutics’ trial have led to a significant drop in the company’s stock value. On the other hand, it raised questions about how regulators handle gene therapies with unclear outcomes but high medical needs.
https://endpts.com/sareptas-confirmatory-duchenne-gene-therapy-study-fails-to-meet-primary-endpoint/
https://endpts.com/sareptas-duchenne-confirmatory-trial-results-set-up-showdown-between-fda-and-companys-bold-talk/
PackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span from vector design and construction to AAV, lentivirus, and mRNA services. With a sharp focus on early-stage drug discovery, preclinical development, and cell and gene therapy trials, we deliver cost-effective, dependable, and scalable production solutions. Leveraging our groundbreaking π-alpha 293 AAV high-yield platform, we amplify AAV production by up to 10-fold, yielding up to 1e+17vg per batch to meet diverse commercial and clinical project needs. Moreover, our tailored mRNA and LNP products and services cater to every stage of drug and vaccine development, from research to GMP production, providing a seamless, end-to-end solution.
Related News
Skyline Therapeutics Receives FDA Orphan Drug Designation for Gene Therapy for Retinitis Pigmentosa
BOSTON & SHANGHAI, September 2, 2024 – Skyline Therapeutics, a gene therapy company focused on innovative treatments for rare and severe diseases, announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) for SKG1108....
Novavax Receives Emergency Use Authorization for Updated Covid-19 Vaccine
Novavax has received emergency use authorization (EUA) from the U.S. Food and Drug Administration (FDA) for its updated Covid-19 vaccine, NVX-CoV2705, joining other vaccine manufacturers in addressing evolving virus variants. The EUA permits the use of Novavax's...
Turn Biotechnologies Reports Historic Skin Cell Rejuvenation Breakthroughs at ESDR this Week
Company will present data from its successful rejuvenation of fibroblasts and keratinocytes to influential gathering of international dermatologists MOUNTAIN VIEW, Calif., Sept. 4, 2024 /PRNewswire/ -- Turn Biotechnologies, a developer of novel mRNA medicines and...
H5 influenza vaccines: What needs to be done to reduce the risk of a pandemic
As the global threat of H5N1 influenza looms with outbreaks across species and continents including the U.S., three international vaccine and public health experts say it is time to fully resource and support a robust strategy to address this and future potential...
Related Services